How can drug companies bear the pressure when the supplement of local medical insurance catalogue is cancelled?

[industry trends of pharmaceutical network] the new version of the medical insurance catalog has been officially implemented since January 1, 2020 As a result, the structure of the catalog and the transfer in and transfer out of products have no subversive change on the whole However, it is worth noting that one of the key points of the new version of the directory is to cancel the authority to adjust the local medical insurance directory After the implementation, the original 15% adjustment authority of the local government was lost, and the power of the medical insurance catalogue was transferred to the State Medical Insurance Bureau In the past, if a drug variety could enter the supplementary medical insurance catalogue of more than half of the provinces in China, or if the sales volume of a drug variety in individual provinces accounted for the majority of the national sales volume, then whether the drug entered the national medical insurance catalogue or not is not very different for enterprises Therefore, when drugs fail to enter the national health insurance, pharmaceutical companies will generally try their best to make their drugs enter the local health insurance catalog through supplement Before that, although the local medical insurance bureau could not adjust the list of class a drugs, it could adjust the list of class B drugs As early as in 2000, the notice on printing and distributing the catalogue of drugs for national basic medical insurance issued by the former Ministry of labor and social security mentioned that the administrative departments of labor and social security of all provinces, autonomous regions and municipalities directly under the central government can adjust the class B drugs in the national drug catalogue by referring to the currently implemented public expenses, the scope of medical drugs for labor insurance, and the local disease spectrum and medication habits The sum of the increased and decreased varieties of class B drugs shall be controlled within 15% of the total number of class B drugs But in fact, the upper limit of 15% is largely ignored - the actual number of supplements in each province is far greater than that Therefore, in July last year, the state issued the opinions on the establishment of the management system of medical insurance treatment list (Draft for comments), emphasizing that all regions should strictly follow the national basic medical insurance drug catalog, and in principle, they should not make their own catalog or use flexible methods to increase the drugs in the catalog The right of 15% of local catalogue adjustment has been clearly recovered, and the local original supplementary varieties should be gradually digested within 3 years, and the national key monitored varieties should be digested preferentially At present, under the guidance of national policy, many provinces have launched actions to integrate with the national medical insurance catalogue On the whole, the days when the next batch of drugs can become popular in the market by entering the local catalogue have passed Under the pressure of clearing up local supplementary varieties, the living space of supplementary varieties in each province will be severely squeezed, or it is necessary to take the initiative to reduce prices substantially to enter the transitional period of clearing In a word, the change of provincial supplementary medical insurance into non-medical insurance varieties may lead to the gradual loss of competitiveness of these drugs due to the lack of medical insurance payment, which is also very unfavorable for related pharmaceutical enterprises How to break through the encirclement has gradually become the focus of attention of the unincorporated enterprises Some insiders said that under the circumstances of canceling the supplement of local medical insurance catalogue, pharmaceutical enterprises have two ways to bear pressure First, the varieties that meet the characteristics of grass-roots drug use should begin to sink to the grass-roots level; second, the varieties that meet the characteristics of DTP retail can be selected to move to the drugstore The varieties that fail to enter the national medical insurance catalogue and the corresponding enterprises should make a breakthrough in the broad out of hospital market, maybe there is still a chance According to the current situation, the policy trend of canceling provincial supplement and bringing more life-saving and emergency drugs into the scope of medical insurance will continue unswervingly in the future under the environment of medical insurance and fee control Pharmaceutical enterprises should take advantage of the three-year transition period, strengthen the development of market depth and breadth on the premise of reasonable, compliant and safe marketing, focus on the optimization and upgrading of product structure, and ensure the sustainable development of enterprise performance.